Abstract: Immune checkpoint inhibitors, represented by programmed death protein-1 (PD-1) inhibitors, have shown promising efficacy in gastric cancer, gradually changing the landscape for treating advanced gastric cancer. Several studies have shown that PD-1 monoclonal antibody exhibits superior therapeutic effect in patients with high expression of programmed death-ligand 1 (PD-L1). Moreover, there is a positive correlation between the treatment effect of PD-1 monoclonal antibodies and the expression level of PD-L1 protein. For patients with negative or low expression of PD-L1, the efficacy of PD-1 monoclonal antibody-based regimens is limited, and there is a trend towards combinations of bispecific antibodies, ADCs, and other drugs. To accurately guide clinical practice, China Anti-Cancer Association Committee of Gastric Cancer organized some experts in the field of gastric cancer to hold several rounds of discussions, systematically summarizing the latest guidelines and evidence from domestic and international sources and combining them with clinical practices in China. The expert consensus was based on the three aspects: pathological examination, treatment for advanced stage and perioperative stage. The aim of this consensus is to improve the science and standardization of gastric cancer diagnosis and treatment, particularly to guide front-line clinicians in their selection and application of immunotherapy.